A method for evaluating renal status in a subject, comprising: performing a plurality of assays configured to detect a plurality of kidney injury markers, the plurality of kidney injury markers comprising Hyaluronic acid, and one or more of Immunoglobulin A, Immunoglobulin G1, Immunoglobulin G2, Insulin-like growth factor-binding protein 7, Alpha-1 antitrypsin, Serum amyloid P component, Metalloproteinase inhibitor 2, Hepatocyte growth factor, Intercellular adhesion molecule 1, Beta-2-glycoprotein 1, Interleukin-1 beta, Neutrophil Elastase, Tumor necrosis factor receptor superfamily member 11B, Interleukin-11, Cathepsin D, C-C motif chemokine 24, C-X-C motif chemokine 6, C-C motif chemokine 13, C-X-C motif chemokines -1, -2, and -3, Matrilysin, Interleukin-2 receptor alpha chain, Insulin-like growth factor-binding protein 3, and Macrophage colony-stimulating factor 1 on a body fluid sample obtained from the subject to provide one or more assay results; and correlating the assay results to the renal status of the subject, wherein said correlating step comprises assigning a likelihood of a future change in renal status to the subject based on the assay results, the future change in renal status comprising future acute renal failure and wherein the correlating comprises comparing an assay result in the form of the Hyaluronic acid concentration to a predetermined threshold selected to be indicative of the likelihood of future acute renal failure wherein Hyaluronic acid is a positive going marker that is elevated in a subject that will progress to future ARF relative to a subject that will not progress to future ARF, and wherein an increased likelihood of progression to ARF is assigned to the subject, when the measured concentration is above the threshold relative to a likelihood assigned when the measured concentration is below the threshold, and wherein the likelihood of future ARF is more or less likely to occur within a period of 48 hours of the time at which the body fluid sample is obtained from the subject. performing a plurality of assays configured to detect a plurality of kidney injury markers, the plurality of kidney injury markers comprising Hyaluronic acid, and one or more of Immunoglobulin A, Immunoglobulin G1, Immunoglobulin G2, Insulin-like growth factor-binding protein 7, Alpha-1 antitrypsin, Serum amyloid P component, Metalloproteinase inhibitor 2, Hepatocyte growth factor, Intercellular adhesion molecule 1, Beta-2-glycoprotein 1, Interleukin-1 beta, Neutrophil Elastase, Tumor necrosis factor receptor superfamily member 11B, Interleukin-11, Cathepsin D, C-C motif chemokine 24, C-X-C motif chemokine 6, C-C motif chemokine 13, C-X-C motif chemokines -1, -2, and -3, Matrilysin, Interleukin-2 receptor alpha chain, Insulin-like growth factor-binding protein 3, and Macrophage colony-stimulating factor 1 on a body fluid sample obtained from the subject to provide one or more assay results; and correlating the assay results to the renal status of the subject, wherein said correlating step comprises assigning a likelihood of a future change in renal status to the subject based on the assay results, the future change in renal status comprising future acute renal failure and wherein the correlating comprises comparing an assay result in the form of the Hyaluronic acid concentration to a predetermined threshold selected to be indicative of the likelihood of future acute renal failure wherein Hyaluronic acid is a positive going marker that is elevated in a subject that will progress to future ARF relative to a subject that will not progress to future ARF, and wherein an increased likelihood of progression to ARF is assigned to the subject, when the measured concentration is above the threshold relative to a likelihood assigned when the measured concentration is below the threshold, and wherein the likelihood of future ARF is more or less likely to occur within a period of 48 hours of the time at which the body fluid sample is obtained from the subject.